Benign Prostatic Hyperplasia Treatment Market to Surpass USD 17.6 Billion by 2028
The rise in benign prostatic hyperplasia prevalence and the expanding worldwide male geriatric population are both important factors driving the growth of the benign prostatic hyperplasia treatments market. In addition, increased sympathetic nerve activity, altered endocrine state, a heightened inflammatory response, and oxidative stress all have a role in the development of benign prostatic hyperplasia in obese individuals. The body's hormonal fluctuations also contribute to benign prostatic hyperplasia by causing prostate enlargement.

